Perrigo Company plc (PIG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Perrigo Company plc (PIG) has a cash flow conversion efficiency ratio of 0.060x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€175.40 Million ≈ $205.06 Million USD) by net assets (€2.94 Billion ≈ $3.43 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PIG company net worth for the company's overall valuation and market capitalisation.
Perrigo Company plc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Perrigo Company plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Perrigo Company plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Perrigo Company plc ranked by their cash flow conversion efficiency. Explore Perrigo Company plc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oric Pharmaceuticals Inc
NASDAQ:ORIC
|
-0.083x |
|
Shandong Sacred Sun Power Sources Co Ltd
SHE:002580
|
0.017x |
|
NAPCO Security Technologies Inc
NASDAQ:NSSC
|
0.072x |
|
Frontier Group Holdings Inc
NASDAQ:ULCC
|
1.110x |
|
Oriental Energy Co Ltd
SHE:002221
|
0.039x |
|
Sakura Development Co Ltd
TW:2539
|
0.185x |
|
Two Harbors Investments Corp
NYSE:TWO
|
0.033x |
|
AFFIN Holdings Bhd
KLSE:5185
|
0.082x |
Annual Cash Flow Conversion Efficiency for Perrigo Company plc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Perrigo Company plc from 2016 to 2025. View today's stock price for Perrigo Company plc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €2.94 Billion ≈ $3.43 Billion |
€238.50 Million ≈ $278.83 Million |
0.081x | -3.30% |
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
€362.90 Million ≈ $424.27 Million |
0.084x | -1.21% |
| 2023-12-31 | €4.77 Billion ≈ $5.57 Billion |
€405.50 Million ≈ $474.07 Million |
0.085x | +34.01% |
| 2022-12-31 | €4.84 Billion ≈ $5.66 Billion |
€307.30 Million ≈ $359.27 Million |
0.063x | +109.18% |
| 2021-12-31 | €5.15 Billion ≈ $6.02 Billion |
€156.30 Million ≈ $182.73 Million |
0.030x | -73.03% |
| 2020-12-31 | €5.66 Billion ≈ $6.61 Billion |
€636.20 Million ≈ $743.78 Million |
0.113x | +68.38% |
| 2019-12-31 | €5.80 Billion ≈ $6.79 Billion |
€387.80 Million ≈ $453.38 Million |
0.067x | -36.14% |
| 2018-12-31 | €5.67 Billion ≈ $6.63 Billion |
€593.00 Million ≈ $693.28 Million |
0.105x | -7.63% |
| 2017-12-31 | €6.17 Billion ≈ $7.21 Billion |
€698.90 Million ≈ $817.09 Million |
0.113x | +3.03% |
| 2016-12-31 | €5.96 Billion ≈ $6.97 Billion |
€654.90 Million ≈ $765.65 Million |
0.110x | -- |
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and ora… Read more